Amgen Inc. vs L'Oréal SA: Strategic Comparison

This in-depth comparison examines Amgen Inc. and L'Oréal SA across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating L'Oréal SA, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and L'Oréal SA is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against ~$49.8B for L'Oréal SA, while their respective market capitalizations stand at $228.2B and $204.9B. Amgen Inc. is headquartered in United States and L'Oréal SA in France, and those different home markets shape how each company competes.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

L'Oréal SA: L'Oréal SA is the world's largest beauty company by sales and market value. Headquartered in Clichy near Paris and listed on Euronext Paris, it runs about 40 international brands through four divisions: Consumer Products, L'Oréal Luxe, Dermatological Beauty and Professional Products. Its categories span skincare, makeup, hair care, hair colour and fragrance. Europe and North America are its largest regions, followed by North Asia and the fast-growing SAPMENA-SSA zone (South Asia Pacific, Middle East, North Africa and Sub-Saharan Africa).

Amgen Inc. and L'Oréal SA pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and L'Oréal SA.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

L'Oréal SA business model: L'Oréal makes money by developing, manufacturing and marketing beauty products that it sells to retailers, pharmacies, salons, travel retail and directly online. Its four divisions had these 2025 sales: Consumer Products ~$18.2 billion (€16.09 billion) (L'Oréal Paris, Maybelline New York, Garnier, NYX), L'Oréal Luxe ~$17.6 billion (€15.60 billion) (Lancôme, YSL Beauty, Armani, Kiehl's, Aesop, Prada, Valentino), Dermatological Beauty ~$8.14 billion (€7.20 billion) (CeraVe, La Roche-Posay, Vichy, SkinCeuticals) and Professional Products ~$5.83 billion (€5.16 billion) (Kérastase, L'Oréal Professionnel, Redken, Matrix). Gross margin is about 74%, which funds heavy spending on advertising and promotion and on research. E-commerce passed 30% of sales in 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of L'Oréal SA.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

L'Oréal SA competitive advantage: L'Oréal's edge comes from three things competitors rarely combine: a portfolio covering mass, luxury, dermatological and salon beauty; a research organisation of roughly 4,000 people that files about 500 patents a year; and distribution in about 150 countries across every channel. Because beauty is its only business, capital and talent are not split with food or household goods, unlike Unilever or Procter & Gamble. Its scale also lets it take long licences from fashion houses such as Armani, Prada, Valentino and Gucci.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and L'Oréal SA each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

L'Oréal SA growth strategy: L'Oréal grows through innovation, acquisitions, licences and new markets. Recent deals include Aesop (2023, about $2.5 billion), a roughly 20% stake in Galderma, and Kering Beauté (2026, ~$4.52 billion (€4 billion)), which brought Creed plus 50-year licences for Bottega Veneta, Balenciaga and Gucci. In India it agreed in 2026 to buy Onesto Labs, owner of the Innovist brands including Bare Anatomy, cleared by the Competition Commission of India in September 2026, and its BOLD venture fund teamed up with Nykaa to take minority stakes in Indian beauty start-ups. Digitally, it uses AI in product development and marketing, and e-commerce is above 30% of sales.

A closer look at the financial trajectory of Amgen Inc. and L'Oréal SA rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

L'Oréal SA: L'Oréal's 2025 sales reached ~$49.8 billion (€44.05 billion), up 4.0% like-for-like and 1.3% as reported because of currency headwinds. Gross profit was ~$37 billion (€32.74 billion) (74.3% of sales), operating profit ~$10 billion (€8.89 billion) (20.2%) and net profit after non-controlling interests ~$6.93 billion (€6.13 billion). Net cash flow rose 7.8% to ~$8.14 billion (€7.2 billion). Growth sped up in 2026: first-quarter sales were ~$13.7 billion (€12.15 billion) (+7.6% like-for-like), and first-half sales were ~$26.9 billion (€23.77 billion), up 6.8% like-for-like and 5.8% reported. First-half operating profit rose 6.8% to ~$5.72 billion (€5.06 billion), a record 21.3% margin, and net profit excluding non-recurring items rose 4.7% to ~$4.47 billion (€3.96 billion). On 28 September 2026 L'Oréal's market value was about $232 billion (€205 billion), with the share near €380.